Venous thromboembolism is a preventable medical condition associated with significant morbidity and mortality. It can lead to deep vein thrombosis, pulmonary embolism, and stroke. Thrombi develop when intravascular conditions promote activation of the coagulation system or when there is an imbalance between endogenous anticoagulants and procoagulants. Such conditions include vascular injury, inflammation, venous stasis, and hypercoagulable states. Anticoagulant medications are indicated for the prevention and treatment of venous thromboembolism. They exert their effect on clotting factors to prevent the formation of thrombi or the propagation of an existing clot. Historically, anticoagulants were limited to heparins and vitamin K antagonists. Over the past 15 years, however, several new anticoagulant medications have been introduced. This article describes commonly prescribed and newer anticoagulants available to health care professionals, including their mechanism of action, therapeutic use, unique characteristics, and available reversal agents in the event of life-threatening bleeding.
Skip Nav Destination
Article navigation
Summer 2019
Symposium|
June 15 2019
Anticoagulant Medications for the Prevention and Treatment of Thromboembolism
Lori Brien, MS, ACNP-BC
Lori Brien, MS, ACNP-BC
Lori Brien is Acute Care Nurse Practitioner, Cardiovascular and Thoracic Surgery, Virginia Hospital Center, Arlington, Virginia, and Assistant Program Director, School of Nursing and Health Studies, Adult Gerontology Acute Care Nurse Practitioner Program, Georgetown University, 3700 Reservoir Rd NW, Washington, DC 20057 ([email protected]).
Search for other works by this author on:
AACN Adv Crit Care (2019) 30 (2): 126–138.
Citation
Lori Brien; Anticoagulant Medications for the Prevention and Treatment of Thromboembolism. AACN Adv Crit Care 15 June 2019; 30 (2): 126–138. doi: https://doi.org/10.4037/aacnacc2019867
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access